NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The agreement partners Voltron with a multi-national company known for enabling companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.
Today’s news comes on the heels of the Company’s announcement of the successful completion of its first small animal safety and immunogenicity study assessing the effect of novel vaccine Halovax™ against COVID-19. The vaccine construct was completed with positive response to selected COVID-19 peptides in conjunction with the self-assembling vaccine prototype. The study demonstrates that selection algorithm for immunogenic peptides is functioning appropriately.
HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ: HOTH).
The company’s vaccines are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the target of the vaccine – which can be a virus or a cancer patient’s tumor. These are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production of the vaccine.
“We are pleased to have executed a manufacturing agreement with an international contract manufacturer for our vaccine portfolio. This initiative builds atop our recent operational momentum, including our recently announced successful preclinical testing of our COVID-19 vaccine candidate. We are now actively moving toward starting clinical trials in humans with the goal of bringing to market proven and effective vaccines to help treat a range of conditions, including various cancers and COVID-19,” said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc.
About Voltron Therapeutics, Inc.
Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital’s novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information please visit www.voltrontx.com.
About HaloVax™, LLC
HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ: HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Investor Contacts:
Matt Duffy
President
Voltron Therapeutics, Inc.
646-335-5923
mduffy@luciuspartnersllc.com
Jason Assad
Investor Relations
Voltron Therapeutics, Inc.
678-570-6791
jwassad@bellsouth.net
